Insights into retention and safety/tolerability of apomorphine sublingual film in patients with Parkinson's disease and OFF episodes: post hoc analyses of a phase III, open-label study.

ABSTRACT:

Background

Managing OFF episodes in patients with Parkinson's disease becomes increasingly challenging over time, making it critical to tailor treatment to each patient's needs and characteristics for effective care.

Objectives

Study CTH-301 assessed the long-term safety/tolerability and efficacy of sublingual apomorphine (SL-APO) for the on-demand treatment of OFF episodes.

Design

The findings from four post hoc analyses of Study CTH-301, conducted to understand factors influencing SL-APO retention and safety/tolerability, with a particular focus on oropharyngeal treatment-emergent adverse events (TEAEs) are reported.

Methods

The first analysis evaluated baseline variables differing between patients who completed the study and those who discontinued due to eit

SUBMITTER: Kassubek J 

PROVIDER: S-EPMC12181698 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature